2022 World Conference on Lung Cancer (ePosters)-EP08.01-064. Serum NY-ESO-1 and XAGE1 Antibodies Predict and Monitor Clinical Responses to Immune Checkpoint Therapy for NSCLC

EP08.01-064. Serum NY-ESO-1 and XAGE1 Antibodies Predict and Monitor Clinical Responses to Immune Checkpoint Therapy for NSCLC

Back to course

Pdf Summary

A study conducted in Japan investigated the use of serum antibodies against cancer-testis antigens (CTA) as predictive biomarkers for response to immune checkpoint (IC) therapy in patients with non-small-cell lung cancer (NSCLC). The researchers developed an automated immunoassay system that measured serum CTA antibodies using a small volume of serum. They analyzed serum samples from 263 NSCLC patients before IC therapy and compared them to samples from non-malignant disease controls. The results showed that NSCLC patients had significantly higher levels of CTA antibodies compared to controls. Among the NSCLC patients, 25.9% had CTA antibody levels above a cutoff value of 10 SU/mL. Patients with CTA antibody levels above 10 SU/mL had the longest overall survival with IC monotherapy compared to those with lower levels. The objective response rate to IC monotherapy was higher in CTA antibody-positive patients compared to antibody-negative patients. During IC therapy, the levels of CTA antibodies correlated well with tumor burden/response. In combination with tumor proportion score (TPS), NSCLC patients with CTA antibody levels above 10 SU/mL and/or TPS above 50% had significantly longer overall survival compared to those with lower levels. The study suggests that CTA antibodies can be used as predictive biomarkers for response to IC monotherapy in NSCLC and also as monitoring markers of response. The high-sensitivity immunoassay used in the study is a non-invasive and rapid diagnostic test for predicting and monitoring IC therapy response. Further research and clinical validation are needed to confirm the findings.

Asset Subtitle

Mikio Oka

Meta Tag

Speaker Mikio Oka

Topic Metastatic Non-small Cell Lung Cancer - Immunotherapy

Keywords

Japan

serum antibodies

cancer-testis antigens

predictive biomarkers

immune checkpoint therapy

non-small-cell lung cancer

automated immunoassay system

serum CTA antibodies

overall survival

tumor burden/response